Concert Pharmaceuticals is a clinical stage biopharmaceutical company applying its knowledge of deuterium chemistry to discover and develop novel small molecule drugs. Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. The Company's approach typically starts with approved drugs that may be improved with deuterium substitution. Concert Pharmaceuticals's technology provides the opportunity to develop products that may compete with the non-deuterated drug in existing markets or to leverage the known activity of approved drugs to expand into new indications. The Company's deuterated chemical entity platform, or DCE Platform, has broad potential across numerous therapeutic areas.
Market capitalization (5-Mar-2018)